RxDoctor Payments Data

Lev Lubarsky, DO

Cardiovascular Disease · East Setauket, NYNPI 1093878399

Payments from drug & device makers

$2,120in general payments, 2019–2025

Across 17 payments — averaging $124.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Canon Medical Systems USA, Inc.$1K
  • Heartflow, Inc.$449
  • Pfizer$148
  • AstraZeneca$125
  • Sunovion Pharmaceuticals Inc.$124
  • Akcea Therapeutics, Inc.$27
  • plus $20 from 1 others

What the payments were for

  • Travel & lodging$1,18156%
  • Food & beverage$93844%

General payments by program year

19
20
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,120 in reported general payments places this provider in the 55th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$1,316,626
Medicare patients
1,979
Services billed
15,356

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban169$267,834
XareltoRivaroxaban49$64,931
EntrestoSacubitril/Valsartan35$55,849
MultaqDronedarone Hcl15$33,187
Repatha SureclickEvolocumab31$21,632
Metoprolol Succinate476$10,447
FarxigaDapagliflozin Propanediol12$9,377
Praluent PenAlirocumab12$8,944
Rosuvastatin Calcium404$6,080
Candesartan Cilexetil56$5,201
Ezetimibe119$3,464
Atorvastatin Calcium358$3,392
Propranolol Hcl ErPropranolol Hcl52$2,271
Valsartan46$1,978
Nebivolol Hcl33$1,921

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$148$267,834169 claims
AstraZenecaFarxiga$125$9,37712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in East Setauket

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →